Enterprise Value
309.7M
Cash
58.66M
Avg Qtr Burn
-13.05M
Short % of Float
4.73%
Insider Ownership
1.44%
Institutional Own.
69.91%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
REZLIDHIA (Olutasidenib) (FT-2102) (IDH1m inhibitor) Details Glioma, Acute myeloid leukemia, Cancer | Approved Quarterly sales | |
TAVALISSE® (fostamatinib disodium hexahydrate) Details Adult Chronic Immune Thrombocytopenia (ITP) | Approved Quarterly sales | |
REZLIDHIA (olutasidenib) Details Cancer, Acute myeloid leukemia | Approved Quarterly sales | |
Phase 3 Data readout | ||
Phase 3 Data readout | ||
R552 Details Rheumatoid arthritis, Autoimmune disease | Phase 2a Data readout | |
R289 Details Lower-risk myeloid dysplastic syndrome | Phase 1b Data readout | |
TAVALISSE® (fostamatinib disodium hexahydrate) Details Blood disorder | Failed Discontinued |